Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin Jandeleit-Dahm

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Nature Clinical Practice. Nephrology|October 27, 2006
Does the risk of developing diabetes in hypertensive kidney disease vary with different antihypertensive agents?Karin Jandeleit-Dahm
Cardiovascular Research|January 20, 2021
Endothelin in diabetes-associated atherosclerosis: opportunity 'NOX'Karin Jandeleit-Dahm
Diabetes|June 20, 2023
Cytochrome-Derived EETs, VEGF-A, and NOX4: Piecing the Puzzle TogetherKarin Jandeleit-Dahm, Jaroslawna Meister
Endocrinology and Metabolism Clinics of North America|September 9, 2006
Hypertension and diabetes: role of the renin-angiotensin systemKarin Jandeleit-Dahm, Mark E Cooper
Journal of Molecular Medicine (Berlin, Germany)|April 2, 2014
The pathobiology of diabetic vascular complications--cardiovascular and kidney diseaseStephen P Gray, Karin Jandeleit-Dahm
Current Opinion in Nephrology and Hypertension|February 22, 2002
Hypertension and diabetesKarin Jandeleit-Dahm, Mark E Cooper
Current Pharmaceutical Design|May 14, 2008
The role of AGEs in cardiovascular diseaseKarin Jandeleit-Dahm, Mark E Cooper
Current Hypertension Reports|September 3, 2004
Antiproteinuric effect of RAS blockade: new mechanismsMarkus Lassila, Mark E Cooper, Karin Jandeleit-Dahm
Handbook of Experimental Pharmacology|August 19, 2020
Inhibitors of Advanced Glycation End Product (AGE) Formation and AccumulationKarly C Sourris, Anna Watson, Karin Jandeleit-Dahm
Journal of the American Heart Association|December 31, 2021
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque InstabilityYung-Chih Chen, Karin Jandeleit-Dahm, Karlheinz Peter
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Nature Clinical Practice. Nephrology|October 27, 2006
Does the risk of developing diabetes in hypertensive kidney disease vary with different antihypertensive agents?Karin Jandeleit-Dahm
Cardiovascular Research|January 20, 2021
Endothelin in diabetes-associated atherosclerosis: opportunity 'NOX'Karin Jandeleit-Dahm
Diabetes|June 20, 2023
Cytochrome-Derived EETs, VEGF-A, and NOX4: Piecing the Puzzle TogetherKarin Jandeleit-Dahm, Jaroslawna Meister
Endocrinology and Metabolism Clinics of North America|September 9, 2006
Hypertension and diabetes: role of the renin-angiotensin systemKarin Jandeleit-Dahm, Mark E Cooper
Journal of Molecular Medicine (Berlin, Germany)|April 2, 2014
The pathobiology of diabetic vascular complications--cardiovascular and kidney diseaseStephen P Gray, Karin Jandeleit-Dahm
Current Opinion in Nephrology and Hypertension|February 22, 2002
Hypertension and diabetesKarin Jandeleit-Dahm, Mark E Cooper
Current Pharmaceutical Design|May 14, 2008
The role of AGEs in cardiovascular diseaseKarin Jandeleit-Dahm, Mark E Cooper
Current Hypertension Reports|September 3, 2004
Antiproteinuric effect of RAS blockade: new mechanismsMarkus Lassila, Mark E Cooper, Karin Jandeleit-Dahm
Handbook of Experimental Pharmacology|August 19, 2020
Inhibitors of Advanced Glycation End Product (AGE) Formation and AccumulationKarly C Sourris, Anna Watson, Karin Jandeleit-Dahm
Journal of the American Heart Association|December 31, 2021
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque InstabilityYung-Chih Chen, Karin Jandeleit-Dahm, Karlheinz Peter
Pageof 7